Abstract

Review Article

Host biomarkers for early diagnosis of infectious diseases: A comprehensive review

Arindam Chakraborty* and Singh Monica

Published: 05 June, 2019 | Volume 2 - Issue 1 | Pages: 001-007

Biomarkers have been used in the diagnosis of disease and other conditions for many decades. There are diverse ranges of analytical targets, including metabolites, nucleic acids and proteins were used as a biomarker. Clinical diagnoses already rely heavily on these for patient disease classification, management, and informing treatment and care pathways. For that there is always a need of rapid and point of care test. However, until fairly recently, studies of biomarker efficacy in a clinical setting were mainly limited to single or dual use, and the landscape was complex, confused, and often inconsistent. Few candidates emerged from this somewhat clouded picture: C-reactive protein, procalcitonin (PCT) for sepsis, ADA for mycobacterium tuberculosis and a Circulating miRNAs serve as molecular markers for diverse physiological and pathological conditions.

Read Full Article HTML DOI: 10.29328/journal.ijcmbt.1001005 Cite this Article Read Full Article PDF

References

  1. Kapasi AJ, Dittrich S, González IJ, Rodwell TC. Host Biomarkers for Distinguishing Bacterial from Non-Bacterial Causes of Acute Febrile Illness: A Comprehensive Review. PLoS ONE. 2016; 11: e0160278. Ref.: http://bit.ly/2MtsKCM
  2. Farrar JHP, Junghanss T, Kang G, Lalloo D, White NJ. Manson's Tropical Diseases. 22nd Edition ed. London, UK: Saunders; 2009. Ref.: http://bit.ly/2ZcWrt9
  3. Zhang X, Guo J, Fan S, Li Y, Wei L, et al. Screening and Identification of Six Serum microRNAs as Novel Potential Combination Biomarkers for Pulmonary Tuberculosis Diagnosis. PLoS ONE. 2013; 8: Ref.: http://bit.ly/2WjBpY6
  4. Kempsell KE, Ball G, Szakmany T. Issues in biomarker identification, validation and development for disease diagnostics in Public Health, Expert Review of Molecular Diagnostics. 2016; 16: 4: 383-386. Ref.: http://bit.ly/2WNP0LC
  5. Pepys MB, Baltz ML. Acute phase proteins with special reference to C-reactive protein and related proteins (pentaxins) and serum amyloid A protein. Adv Immunol. 1983; 34:141–212. Ref.: http://bit.ly/2XsecnW
  6. Du Clos TW, Mold C. C-reactive protein: an activator of innate immunity and a modulator of adaptive immunity. Immunol Res. 2004; 30: 261–277. Ref.: http://bit.ly/2Wj7dfR
  7. Shine B, de Beer FC, Pepys MB. Solid phase radioimmunoassays for C-reactive protein. Clin Chim Acta. 1981; 117: 13–23. Ref.: http://bit.ly/2QY5Z8R
  8. Elsing C, Ernst S, Kayali N, Stremmel W, Harenberg S. Lipopolysaccharide binding protein, interleukin- 6 and C-reactive protein in acute gastrointestinal infections: value as biomarkers to reduce unnecessary antibiotic therapy. Infection. 2011; 39: 327–331. Ref.: http://bit.ly/2IzBNx1
  9. Weh J, Antoni C, Weiss C, Findeisen P, Ebert M, et al. Discriminatory potential of C-reactive protein, cytokines, and fecal markers in infectious gastroenteritis in adults. Diagn Microbiol Infect Dis. 2013; 77: 79–84. Ref.: http://bit.ly/2K49vOa
  10. Diez-Padrisa N, Bassat Q, Machevo S, Quinto L, Morais L, et al. Procalcitonin and Creactive protein for invasive bacterial pneumonia diagnosis among children in Mozambique, a malariaendemic area. PLoS One. 2010; 5: e13226. Ref.: http://bit.ly/2Wio2Hw
  11. Tamune H, Takeya H, Suzuki W, Tagashira Y, Kuki T, et al. Cerebrospinal fluid/blood glucose ratio as an indicator for bacterial meningitis. The American journal of emergency medicine. 2014; 32: 263–266. Ref.: http://bit.ly/2HWKa6o
  12. Viallon A, Desseigne N, Marjollet O, Birynczyk A, Belin M, et al. Meningitis in adult patients with a negative direct cerebrospinal fluid examination: value of cytochemical markers for differential diagnosis. Critical care. 2011; 15: R136. Ref.: http://bit.ly/31g4EPt
  13. Ibrahim KA, Abdel-Wahab AA, Ibrahim AS. Diagnostic value of serum procalcitonin levels in children with meningitis: a comparison with blood leukocyte count and C-reactive protein. J Pak Med Assoc. 2011; 61: 346–351. Ref.: http://bit.ly/2IkH2Af
  14. Pfister R, Kochanek M, Leygeber T, Brun-Buisson C, Cuquemelle E, et al. Procalcitonin for diagnosis of bacterial pneumonia in critically ill patients during 2009 H1N1 influenza pandemic: a prospective cohort study, systematic review and individual patient data meta-analysis. Critical care. 2014; 18: R44. Ref.: http://bit.ly/2wBF2OG
  15. Meisner M. Update on procalcitonin measurement. Ann Lab Med. 2014; 34: 263-273. Ref.: http://bit.ly/2IgiKr2
  16. Gogos CA, Drosou E, Bassaris HP, Skoutelis A. Pro- versus anti-inflammatory cytokine profile in patients with severe sepsis: a marker for prognosis and future therapeutic options. J Infect Dis. 2000; 181: 176-180. Ref.: http://bit.ly/2WrXqsO
  17. Schuetz P, Albrich W, Mueller B. Procalcitonin for diagnosis of infection and guide to antibiotic decisions: past, present and future. BMC Med. 2011; 9: 107. Ref.: http://bit.ly/2MuS37y
  18. Becker KL, Nylén ES, White JC, Müller B, Snider RH Jr. Procalcitonin and the Calcitonin Gene Family of Peptides in Inflammation, Infection, and Sepsis: A Journey from Calcitonin Back to Its Precursors. J Clin Endocrinol Metab. 2004; 89: 1512-1525. Ref.: http://bit.ly/2KvybhU
  19. van Nieuwkoop C, Bonten TN, van’t Wout JW, Kuijper EJ, Groeneveld GH, et al. Procalcitonin reflects bacteremia and bacterial load in urosepsis syndrome: a prospective observational study. Crit Care. 2010; 14: R206. Ref.: http://bit.ly/2K06RZA
  20. Christ-Crain M, Stolz D, Bingisser R, Muller C, Miedinger D, et al. Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med. 2006; 174: 84-93. Ref.: http://bit.ly/2WepElT
  21. Schuetz P, Mueller B, Trampuz A. Serum procalcitonin for discrimination of blood contamination from bloodstream infection due to coagulase negative staphylococci. Infection. 2007; 35: 352-355. Ref.: http://bit.ly/31bqm6S
  22. Muller F, Christ-Crain M, Bregenzer T, Krause M, Zimmerli W, et al. Procalcitonin levels predict bacteremia in patients with community-acquired pneumonia: a prospective cohort trial. Chest. 2010; 138: 121-129. Ref.: http://bit.ly/2XsLCTy
  23. Hochreiter M, Köhler T, Schweiger A, Keck F, Bein B, et al. Procalcitonin to guide duration of antibiotic therapy in intensive care patients: a randomized prospective controlled trial. Crit Care. 2009; 13: R83. Ref.: http://bit.ly/2Zawv1y
  24. Nobre V, Harbarth S, Graf JD, Rohner P, Pugin J. Use of procalcitonin to shorten antibiotic treatment duration in septic patients: a randomized trial. Am J Respir Crit Care Med. 2008; 177: 498-505. Ref.: http://bit.ly/2WgZQFF
  25. Christ-Crain M, Muller B. Procalcitonin in bacterial infections–hype, hope, more or less? Swiss Med Wkly. 2005; 135: 451-460. Ref.: http://bit.ly/2WkYmKl
  26. Uzzan B, Cohen R, Nicolas P, Cucherat M, Perret GY. Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: a systematic review and meta-analysis. Crit Care Med. 2006; 34: 1996-2003. Ref.: http://bit.ly/2HWKNNi
  27. Hunziker S, Hugle T, Schuchardt K, Groeschl I, Schuetz P, et al. The value of serum procalcitonin level for differentiation of infectious from noninfectious causes of fever after orthopaedic surgery. J Bone Joint Surg Am. 92: 138-148. Ref.: http://bit.ly/2ETedtK
  28. Kaya S, Cetin ES, Aridogan BC, Arikan S, Demirci M. Adenosine deaminase activity in serum of patients with hepatitis - a useful tool in monitoring clinical status. J Microbiol Immunol Infect. 2007; 40: 288-292. Ref.: http://bit.ly/31e5z2A
  29. Cimen F, Ciftci TU, Berktas BM. The relationship between serum adenosine deaminase levels in lung tuberculosis along with drug resistance and the category of tuberculosis. Turkish Respir J. 2008; 9: 20-23.
  30. Gakis C. Adenosine deaminase (ADA) isoenzymes ADA1 and ADA2: diagnostic and biological role. Eur Respir J. 1996; 9: 632-633. Ref.: http://bit.ly/317ujcZ
  31. Greco S, Girardi E, Masciangelo R, Capoccetta GB, Saltini C. Adenosine Deaminase and interferon gamma measurements for the diagnosis of tuberculous pleurisy: a metaanalysis. Int J Tuberc Lung Dis. 2003; 7: 777-786. Ref.: http://bit.ly/2QOTEDL
  32. Saleh MA, Hammad E, Ramadan MM, Abd El-Rahman A, Enein AF. Use of adenosine deaminase measurements and QuantiFERON in the rapid diagnosis of tuberculous peritonitis. J Med Microbiol. 2012; 61: 514–519. Ref.: http://bit.ly/2WrZy3w
  33. Barua R, Hossain M. Adenosine deaminase in diagnosis of tuberculosis: a review. Anwer Khan Mod Med Coll J. 2014; 5: 43–48. Ref.: http://bit.ly/2QPyOnR
  34. Jhamaria JP, Jenaw RK, Luh SK, Mathur DK, Parihar HL, et al. Serum adenosine deaminase (ADA) in differential diagnosis of pulmonary tuberculosis and common non tubercular respiratory diseases. Ind J Tub. 1988; 35: 25–27. Ref.: http://bit.ly/2WrDhTv
  35. Agarwal MKN, Mukerji PK, Srivastava VML. A study of serum adenosine deaminase activity in sputum negative patients of pulmonary tuberculosis. Ind L Tub. 1991; 38: 139. Ref.: http://bit.ly/2MvQ1UQ
  36. Gupta BK, Bharat V, Bandyopadhyay D. Sensitivity, specificity, negative and positive predictive values of adenosine deaminase in patients of tubercular and non-tubercular serosal effusion in India. J Clin Med Res. 2010; 2: 121–126. Ref.: http://bit.ly/2IinyfK
  37. Hammond SM. MicroRNAs as oncogenes. Curr Opin Genet Dev. 2006; 16: 4-9. Ref.: http://bit.ly/2K0Q2y0
  38. O'Connell RM, Rao DS, Chaudhuri AA, Baltimore D. Physiological and pathological roles for microRNAs in the immune system. Nat Rev Immunol. 2010; 10: 111-122. Ref.: http://bit.ly/2Z6ZVxq
  39. Wang T, Qian X, Wang Z, Wang L, Yu L, Ding Y, et al. Detection of cell free BIRC5 mRNA in effusions and its potential diagnostic value for differentiating malignant and benign effusions. Int J Cancer. 2009; 125: 1921-1925. Ref.: http://bit.ly/2WiqWvU
  40. Faruq O, Vecchione A. microRNA: Diagnostic perspective. Front Med Lausanne. 2015; 2: 51. Ref.: http://bit.ly/2QMKcRl
  41. Pandey RK, Sundar S, Prajapati VK. Differential Expression of miRNA Regulates Tcell differentiation and plasticity during visceral leishmaniasis infection. Front. Microbiol. 2016; 7: 206. Ref.: http://bit.ly/2QSHLwv
  42. Almeida MI, Reis RM, Calin GA. MicroRNA history: discovery, recent applications, and next frontiers. Mut Res. 2011; 717: 1–8. Ref.: http://bit.ly/2HWDhC9
  43. Verma P, Pandey RK, Prajapati P, Prajapati VK. Circulating microRNAs: potential and emerging biomarkers for diagnosis of human infectious diseases. Front Microbiol. 2016; 7: 01274: 1-7. Ref.: http://bit.ly/2Z70lE0
  44. Ojha R, Nandani R1, Pandey RK1, Mishra A2, Prajapati VK. Emerging role of circulating microRNA in the diagnosis of human infectious diseases. J Cell Physiol. 2019; 234: 1030-1043. Ref.: http://bit.ly/2wKkVOd
  45. Eck M, Schmausser B, Scheller K, Toksoy A, Kraus M, et al. CXC chemokines Gro(alpha)/IL-8 and IP-10/MIG in Helicobacter pylori gastritis. Clin Exp Immunol. 2000; 122: 192–199. Ref.: http://bit.ly/2JYto9j
  46. Salvatore CM, Techasaensiri C, Tagliabue C, Katz K, Leos N, et al. Tigecycline therapy significantly reduces the concentrations of inflammatory pulmonary cytokines and chemokines in a murine model of Mycoplasma pneumoniae pneumonia. Antimicrob Agents Chemother. 2009; 53: 1546–1551. Ref.: http://bit.ly/2QML6gH
  47. de Fost M, Chierakul W, Pimda K, Dondorp AM, White NJ, et al. Activation of cytotoxic lymphocytes in patients with scrub typhus. Am J Trop Med Hyg. 2005; 72: 465–467. Ref.: http://bit.ly/2ZcY2z9
  48. Lettinga KD, Weijer S, Speelman P, Prins JM, Van Der Poll T, et al. Reduced interferon-gamma release in patients recovered from Legionnaires' disease. Thorax. 2003; 58: 63–67. Ref.: http://bit.ly/2Z4XueE
  49. Shiraki Y, Ishibashi Y, Hiruma M, Nishikawa A, Ikeda S. Candida albicans abrogates the expression of interferon-gamma-inducible protein-10 in human keratinocytes. FEMS Immunol Med Microbiol. 2008; 54: 122–128. Ref.: http://bit.ly/2EThIR6
  50. Liu M, Guo S, Hibbert JM, Jain V, Singh N, et al. CXCL10/IP-10 in infectious diseases pathogenesis and potential therapeutic implications. Cytokine Growth Factor Rev. 2011; 22: 121–130. Ref.: http://bit.ly/2HWN5Mo

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More